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Cancer  arises  in the  context  of  an  in vivo  tumor  microenvironment.  This  microenvironment  is  both  a
cause  and  consequence  of tumorigenesis.  Tumor  and  host  cells  co-evolve  dynamically  through  indirect
and direct  cellular  interactions,  eliciting  multiscale  effects  on many  biological  programs,  including  cellu-
lar proliferation,  growth,  and  metabolism,  as  well  as angiogenesis  and  hypoxia  and  innate  and  adaptiveumor microenvironment
ancer biology
immunity.  Here  we  highlight  speciﬁc  biological  processes  that  could  be  exploited  as targets  for  the  pre-ancer therapy
ancer prevention
vention and  therapy  of cancer.  Speciﬁcally,  we describe  how  inhibition  of  targets  such  as  cholesterol
synthesis  and  metabolites,  reactive  oxygen  species  and  hypoxia,  macrophage  activation  and  conversion,
indoleamine  2,3-dioxygenase  regulation  of dendritic  cells,  vascular  endothelial  growth  factor  regula-
tion  of  angiogenesis,  ﬁbrosis  inhibition,  endoglin,  and  Janus  kinase  signaling  emerge  as  examples  of
important  potential  nexuses  in  the regulation  of  tumorigenesis  and  the  tumor  microenvironment  that  can
∗ Corresponding author at: Division of Oncology, Departments of Medicine and Pathology, Stanford University, Stanford, CA 94305, United States. Tel.: +1 6507256353.
E-mail  address: dfelsher@stanford.edu (D.W. Felsher).
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be targeted.  We  have  also  identiﬁed  therapeutic  agents  as  approaches,  in  particular  natural  products
such as  berberine,  resveratrol,  onionin  A,  epigallocatechin  gallate,  genistein,  curcumin,  naringenin,  des-
oxyrhapontigenin,  piperine,  and  zerumbone,  that may  warrant  further  investigation  to  target  the  tumor
microenvironment  for  the treatment  and/or  prevention  of  cancer.
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Our priority was  to choose targets and approaches after con-
sideration of potential cross-hallmark effects. We  examined for©  2015  Els
. Introduction
.1. Tumor microenvironment as a therapeutic target
The tumor microenvironment is critical to both the initiation
nd maintenance of tumorigenesis [1,2]. The tumor microenviron-
ent is composed of a complex network that includes multipotent
tromal cells/mesenchymal stem cells, ﬁbroblasts, blood vessels,
ndothelial cell precursors, immune cells, and secreted factors such
s cytokines [2]. During tumor progression, changes in the microen-
ironment occur through effects on a molecular as well as cellular
evel and involve interactions between incipient cancer cells and
ost structural as well as adaptive and innate immune cells [3].
any of the “hallmarks of cancer” are related to the tumor microen-
ironment, including the ability to induce proliferation and inhibit
poptosis, to induce angiogenesis and avoid hypoxia, to inhibit
he immune system and avoid immune detection, and to activate
mmune cells to support invasion and metastasis [4]. Speciﬁc onco-
enic pathways can be associated with dramatic changes in the
umor microenvironment [5–8]. Hence, the manipulation of the
umor microenvironment could be used as an approach to prevent
s well as treat cancer.
Identiﬁcation of therapeutic targets in the tumor microenviron-
ent could be useful in the treatment and prevention of cancer.
he typical biological approach has been to investigate speciﬁc
olecular and cellular mechanisms and then to examine whether
r not the inhibition or activation has the expected consequences
or tumorigenesis. However, there are caveats to this approach. The
ame molecules and effector cells can have roles in both the pre-
ention and initiation of tumorigenesis. Different cancers can occur
hrough disparate mechanisms. What is limiting in some contexts
ay  be in other circumstances of no importance. Some targets may
ave effects on multiple pathways and programs that can counter-
ct their overall effectiveness. Hence, the ability to reconcile how
o target the microenvironment and identify suitable therapies is
aunting.
In this review, we have taken a different approach. Through an
nitiative supported by the Halifax Project, a group of investiga-
ors worked together as a team to identify both speciﬁc targets
nd novel approaches to therapeutically inhibit speciﬁc aspects
f the tumor microenvironment. Through an integrative approach
e have identiﬁed strategies for the treatment and prevention
f cancer. Then, we examined the literature and thereby identi-
ed possible agents, in particular natural products, which could
otentially inhibit some or several of these targets. Our goal was to
dentify existing agents that may  be exploited for the prevention
nd/or treatment of cancer. Finally, the team utilized a cross-
alidation approach to examine how these targets and approaches,
ither alone or in combination, could be useful for the prevention
nd/or treatment of cancer.
We identiﬁed 10 programs that could be or deﬁnitely appear to
e targets and 10 existing natural agents that may  mediate their
eported anti-cancer effects through the tumor microenvironment
Figs. 1 and 2, Tables 1 and 2). Our list is not a complete examina-
ion of all possible targets or therapeutic approaches but rather an
ttempt to identify existing broad-spectrum, lower toxicity thera-
eutics that could be combined with existing therapeutics. Ltd.  This  is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
The targets identiﬁed include metabolic programs that may
broadly inﬂuence many cell biology programs that impact tumori-
genesis and the tumor microenvironment, including (cholesterol
synthesis and metabolites, reactive oxygen species (ROS) and
hypoxia, inﬂammation, innate and adaptive immunity related
programs (macrophage conversion, dendritic cell (DC) activation,
immune signaling), host microenvironment associated cellular
programs (ﬁbrosis, angiogenesis), and cytokine mediated regula-
tory programs (interleukin (IL)-6, endoglin, and Janus-associated
kinase (JAK)) (Fig. 1, Tables 1 and 2).
We  particularly focused on identifying approaches for inhib-
iting these targets, including natural products that may have
signiﬁcant anticancer activity. Some of these molecules may
more generally inﬂuence tumorigenesis and the microenviron-
ment (berberine), others more speciﬁcally target ROS (resvera-
trol, desoxyrhapontigenin) macrophage conversion (onionin A),
indoleamine 2,3-dioxygenase (IDO) regulation of dendritic cells
(epigallocatechin-3-gallate (EGCG)), cholesterol synthesis (genis-
tein), ﬁbrosis (naringenin), inﬂammation and immune signaling
(piperine), vascular endothelial growth factor (VEGF) inhibition
(curcumin), and JAK signaling (zerumbone). These approaches may
warrant further investigation (Fig. 1, Tables 1 and 2). These agents
generally have low toxicity, suggesting that they could be combined
with each other or existing therapies.
1.2. Cross-validation of approaches and targets
We  identiﬁed approaches and targets through the analysis of
the scientiﬁc literature via a team of investigators from a multitude
of subspecialties. We  made several assumptions. First, the com-
plex biology and heterogeneity of cancer suggested that the most
effective therapeutic approach may  require simultaneous actions
on mechanisms that are important for many of the hallmarks of
cancer. Second, we anticipated that synergies would be achieved by
combining speciﬁc targets with speciﬁc approaches. Third, we  con-
sidered that we could validate both targets and approaches through
a cross-validation through the analysis of literature. Finally, we  con-
sidered it was  important to examine the relevance of the identiﬁed
targets and the nominated approaches across different aspects of
cancer biology.
Notably, the targets and approaches that we identiﬁed for
the tumor microenvironment have been shown to be relevant to
other cancer hallmarks. These are noted as having “complemen-
tary” effects, while those that were found to have pro-tumorigenic
actions were noted as having “contrary” effects. Instances where
reports on relevant actions in other aspects of cancer biology
were mixed, where reports showing both pro-cancer potential and
anti-tumorigenic potential, we  have used the term “controversial.”
Finally, in instances where no literature support was found to doc-
ument the relevance of a target site or approach in a particular
aspect of cancer’s biology, we documented this as “no known rela-
tionship.” These validation results are shown in Tables 1 and 2.possible incidental actions from therapeutic interventions. We
assembled a reasonably complete view of the literature. However,
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Table 1
Cross-validation of tumor microenvironment targets – prioritized targets were evaluated for known effects in other cancer hallmark areas.
Other cancer
hallmarks
Tumor microenvironment targets
Cholesterol
synthesis
(inhibition)
ROS
(inhibition)
M2
macrophage
conversion
(inhibition)
IDO (inhibition) Cholesterol
metabolites
(inhibition)
VEGF (inhibition) Fibrosis
(inhibition)
IL-6
(inhibition)
Endoglin
(inhibition)
JAK (inhibition)
Genomic
instability
+ [426] 0 0 0 0 + [427] 0 + [428] 0 0
Sustained
proliferative
signaling
+  [429,430] + [431–433] 0 + [434,435] + [436–438] + [439,440] + [441,442] + [170,443] +/− [444,445] + [446,447]
Tumor
promoting
inﬂamma-
tion
0 + [448] + [449,450] + [451] 0 + [452,453] + [364] + [454] 0 + [223]
Evasion of
anti-growth
signaling
+ [455,456] +/− [457,458] + [459] 0 + [455,460] + [461,462] 0 + [463,464] + [465,466] + [467,468]
Resistance to
apoptosis
+ [469] + [470] + [471] + [472] + [473] +/− [474,475] + [476–478] + [479,480] + [481,482] + [483]
Replicative
immortality
+/− [484–486] +/− [487–490] 0 0 0 +/− [491,492] 0 +/− [493,494] 0 + [495,496]
Dysregulated
metabolism
+ [497,498] + [499,500] 0 +/− [435,501] + [502,503] +/− [504–506] 0 + [507] 0 + [508]
Immune
system
evasion
+ [509] + [510–512] + [513,514] + [116,515–517] + [509] + [518–520] + [521] +/− [522,523] 0 + [512,524]
Angiogenesis 0 0 + [525] + [526] 0 + [527] 0 +/− [453,528] + [529] + [223]
Tissue invasion
and
metastasis
+ [530,531] + [532,533] + [513,534] + [535,536] + [537,538] + [539–541] + [542,543] + [544] + [545,546] + [467,547]
Targets that were found to have complementary, anti-carcinogenic actions reported in another hallmark area were indicated with “+”, while targets that were found to have pro-carcinogenic actions in another hallmark area
were  indicated with “−”. In instances where reports on relevant actions in other hallmark areas were mixed (i.e., reports showing both anti-carcinogenic potential and pro-carcinogenic potential), the symbol “+/−” was used.
Finally,  in instances where no literature support was found to document the relevance of a target in a particular aspect of cancer’s biology, we documented this as “0”.
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Table 2
Cross-validation of approaches and hallmarks of cancer. Selected approaches were evaluated for reported actions in other cancer hallmark areas.
Other cancer
hallmarks
Phytochemical approaches
Berberine Resveratrol Onionin A EGCG Genistein Curcumin Naringenin Desoxyrhapontigenin Piperine Zerumbone
Genomic
instability
+ [548,549] + [550,551] 0 +/− [552,553] + [554–556] + [557,558] + [559] 0 + [560,561] 0
Sustained
proliferative
signaling
+  [562,563] + [284,564] 0 + [565,566] +/− [567–571] + [572,573] + [574] 0 [387] + [391,575] + [413,576]
Tumor
promoting
inﬂamma-
tion
0 + [577,578] 0 0 0 + [579] + [364] 0 0 0
Evasion  of
anti-growth
signaling
+ [580,581] + [582] 0 + [583] + [584] + [579,585] 0 0 + [586] 0
Resistance  to
apoptosis
+ [587,588] + [589] 0 + [590] + [591] + [592] +/− [593,594] + [387] + [560] + [595]
Replicative
immortality
+ [581,596] + [597,598] 0 + [599,600] + [601,602] + [603–605] 0 0 0 0
Dysregulated
metabolism
+  [606,607] + [608–610] 0 + [611–614] + [615,616] + [617–619] + [574,620] 0 + [391,621] + [415,622]
Immune
system
evasion
− [623–625] +/− [626–631] 0 + [632–636] +/− [637,638] +/− [639–642] +/− [364,643,644] 0 − [645–648] + [418,649]
Angiogenesis + [650] + [651] 0 0 + [652] + [653] 0 0 0 0
Tissue  invasion
and
metastasis
+ [654,655] + [627,656] 0 + [657,658] +/− [659,660] + [661,662] + [364,366,663] 0 + [400,403] + [664,665]
Approaches that were found to have complementary, anti-carcinogenic actions in a particular hallmark area were were indicated with “+”, while approaches that were found to have pro-carcinogenic actions in a particular
hallmark  area were indicated with “−”. In instances where reports on relevant actions in other hallmarks were mixed (i.e., reports showing both anti-carcinogenic and pro-carcinogenic potential), the symbol “+/−”  was  used.
Finally,  in instances where no literature support was  found to document the relevance of an approach in a particular aspect of cancer’s biology, we documented this as “0”.
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Fig. 1. Targets and approaches identiﬁed that could modulate the tumor microenvironment to prevent or treat cancer. Key therapeutic targets identiﬁed include the
inhibition of cholesterol synthesis and metabolites, reactive oxygen species and hypoxia, macrophage activation and conversion, IDO regulation of DCs, VEGF regulation
of  angiogenesis, ﬁbrosis inhibition, endoglin, and JAK signaling. Potential therapeutic targets that have been identiﬁed and cross-validated, include many natural products
including berberine, resveratrol, onionin A, EGCG, genistein, curcumin, naringenin, desoxyrhapontigenin, piperine, and zerumbone. These may  warrant investigation as
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resented is not unique and other possibilities do exist.
e recognize that our results are a starting point. Future research on
herapeutic combinations will require empirical testing of mixtures
f constituents.
In some instances, published evidence of cross-hallmark rela-
ionships is robust. In other cases, the underlying evidence
as weak, consisting of only a single in vitro study involving
 single cell type. Dose levels and cell/tissue types were not
sed to discriminate when gathering together these reported
ctions. Hence, our results serve as a starting point, with caveats
n mind and a degree of caution. We  believe this heuristic
pproach will be useful to consider synergies that might be antic-
pated in testing that involves certain targets and/or mixtures of
hemical constituents that are being considered for therapeutic
ffects.
. Targets
.1. Cholesterol synthesis and its metabolites
The cholesterol pathway has general importance in the patho-
enesis of many disease states, including cancer, through the
egulation of cellular signaling, oncogene activation, hormone
ignaling, inﬂammation, and immune response, amongst many
ossible contributions.
Cholesterol synthesis and metabolites are intimate to the
athophysiology of carcinogenesis [9–11]. Cholesterol and its
etabolites have an inﬂuence on many biological programs
hat are critical to cellular growth and signaling. Cholesterol
nd its metabolites are integral to the structure and ﬂuidity of
ellular membranes and are the templates for hormones andnt and prevention of cancer, although the speciﬁc target-approach combination as
messengers and regulate cellular signaling and activation of onco-
genes. Cholesterol is critical to normal host cellular and immune
function. Cholesterol is specially localized in lipid rafts, which
are membrane microdomains that assemble the signal trans-
duction machinery and associate with proteins involved in key
cellular signaling pathways. Many of these pathways closely
associate with malignant transformations due to their effect on
organization of the cytoskeleton, cell polarity, and angiogenesis
[12].
Cholesterol was ﬁrst identiﬁed in gallstones [13]. Subsequently,
cholesterol was  found to be important for many biological pur-
poses, including core body temperature, the structural integrity
and ﬂuidity of cellular membranes, the production of bile salts,
the synthesis of hormones such as vitamin D, testosterone,
progesterone, cortisol and estradiol, the regulation of cellular
signaling and activation of many gene products [9,10]. Indeed,
cholesterol and its metabolites are critical to the regulation
via prenylation of many oncogenes including RAS and perhaps
MYC  [14,15]. Cholesterol biosynthesis generally appears to be
altered in cancer cells and its inhibition can impede tumorigen-
esis [16]. Hence, understanding cholesterol’s metabolism could be
important to understanding potential therapeutic approaches for
cancer.
Cholesterol biosynthesis has been well deﬁned [16,17]. Choles-
terol is generally synthesized in the liver beginning with one
molecule each of acetyl CoA and acetoacetyl CoA [18]. Choles-
terol is regulated in the endoplasmic reticulum by sterol regulatory
element-binding protein (SREBP) 1 and 2 [19]. Cholesterol syn-
thesis is controlled by a single enzymatic reaction mediated by
beta-hydroxy-beta-methylglutaryl CoA reductase (HMG-CoA) [20].
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tig. 2. The structures of natural products identiﬁed that may  target the tumor m
erberine, resveratrol, onionin A, EGCG, genistein, curcumin, naringenin, desoxyrha
Many studies suggest that cholesterol and its metabolites play
 fundamental role in tumorigenesis.
First, mouse model studies suggest that cholesterol biosynthe-
is is causative for tumorigenesis [21–23]. Similarly, in transgenic
ouse models of oncogene-induced lymphoma and liver cancer,
umorigenesis is prevented when mice are treated with inhibitors
f HMG-CoA reductase [24,25], which was found to be associated
ith the inhibition of RAS and MYC  oncogenes, respectively.
Second, epidemiological studies have shown that patients
eceiving agents that inhibit cholesterol metabolism reduce the risk
f cancer [26]. Notably, serum cholesterol and cancer risk appears
o depend upon the site of cancer [27].Third, other studies have been reported demonstrating
ncreased levels of cholesterol in tumors compared to normal tis-
ue [28,29]. Fourth, cancers often exhibit alterations in programs
hat regulate cholesterol biosynthesis through the upregulationnvironment for the treatment or prevention of cancer. Molecules shown include
genin, piperine, and zerumbone.
of HMG-CoA reductase activity [30,31], loss of feedback inhibi-
tion [20], increased uptake of extracellular cholesterol through
the LDL receptor [32,33] and decreased expression of choles-
terol exporter ATP binding cassette transporter A1 (ABCA1)
[33–35]. Finally, obesity and high cholesterol level is associated
with increased risk of breast cancer in postmenopausal women
[11,36].
Cholesterol metabolites play a key role in the regulation of
cellular and nuclear oncogene activation. Cholesterol metabolites
are key to the regulation of many oncogenes through prenylation
including the RAS oncogene [25]. In turn, this leads to the regu-
lation of the MYC  oncogene [24,25]. Thus, cholesterol metabolism
is likely playing a role in tumorigenesis. Cholesterol is a key com-
ponent of cellular membranes, a metabolite required to regulate
oncogene activation, and a template for critical hormones. The
potential importance of cholesterol biosynthesis in cancer has led
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o signiﬁcant interest in the use of HMG-CoA reductase inhibitors,
tatins, for the treatment or prevention of human cancer [37–41].
.2. ROS
ROS inﬂuences the tumor microenvironment through many
echanisms that may  be important for the treatment and pre-
ention of cancer [42]. ROS can be deﬁned as oxygen radicals
nd non-radical oxidizing agents that can be easily converted to
adicals containing one or more unpaired electrons [43]. Major
nzymes implicated in the generation of ROS are nicotinamide
denine dinucleotide phosphate (NADPH), myeloperoxidase (MPO)
nd xanthine oxidoreductase (XOR). The non-enzymatic reaction
hat produces ROS is through the mitochondria and generally
nvolves the use of “catalytic” iron or copper ions. ROS are
nvolved in various metabolic processes and enzyme reactions in
he cells, in electron transport chain in the mitochondria, gene
xpression, signal transduction, activation of transcription factors
44,45]. Excess production of ROS may  ultimately lead to tissue
amage [43].
ROS contributes to tumorigenesis through mutagenesis as well
s effects on the tumor microenvironment [46]. ROS levels in can-
er cells are higher compared to those present in the normal cells
47,48], as cancer cells produce ROS via mitochondria [49]. Dysreg-
lation of the anti-oxidant machinery of the mitochondrial matrix
as been shown to contribute signiﬁcantly during cellular trans-
ormation. This is achieved by enhancement in the levels of ROS in
he matrix [49] that may  play an important role in the regulation
f ROS [50–52].
The regulation of ROS is important to tumorigenesis. The mito-
hondrial enzyme superoxide dismutase 2 (SOD2) [53,54] regulates
umor hypoxia [55]. Oncogenes and tumor suppressor genes are
egulated by ROS, including the phosphatase and tensin homologue
PTEN) tumor suppressor [56,57], the mitogen activated protein
inase (MAPK), and the extracellular signal regulated kinases (ERK)
athway [58–60]. ROS levels have been shown to inﬂuence tumor
ngiogenesis [61] and regulate tumor self-renewal/stemness asso-
iated with cancer stem cells [62]. Finally, the anti-neoplastic
roperties of some therapeutic agents may  be mediated by their
ntioxidant properties [63], including tamoxifen [63,64] and sul-
hasalazine [65,66]. The manipulation of ROS levels could be
herapeutically exploited for the treatment and prevention of can-
er.
.3. Macrophage conversion
Macrophage function and regulation contribute to tumorigen-
sis. Tumor associated macrophages (TAMs) and other innate
mmune cells have been found to regulate the tumor microen-
ironment, including the promotion of angiogenesis, initiation of
brosis, and suppression of immune detection [67]. Recently, it
as emerged that tumors can secrete factors that promote the con-
ersion of macrophages from an “M1” to an “M2” phenotype [68].
hysiologically activated macrophages, or M1-type macrophages,
roduce cytokines such as IL-1, IL-8, IL-12, IL-15, IL-18, IL-23 and
umor necrosis factor (TNF)- in response to signaling through toll-
ike receptors triggered by damage associated molecular patterns
resent on bacteria, fungi, viruses and parasites [68]. These acute
nﬂammatory mediators, in particular, IL-12, promote the devel-
pment of a Th1 immune response to eliminate foreign pathogens
nd cancer cells [69]. However, macrophages within tumors are
ot exposed to danger signals and produce higher levels of IL-10, cytokine that alters the differentiation of T cells away from the
ytotoxic Th1 response [70]. M2  macrophages also secrete higher
evels of transforming growth factor (TGF)-,  a cytokine that can
ampen the ability of T cells to mount a targeted response and may Biology 35 (2015) S199–S223 S205
lead to cancer cells attaining stem cell like features [71]. TGF-
also induces the activation of ﬁbroblasts and other mesenchymal
cells that eventually leads to tissue ﬁbrosis. Thus, tumor associ-
ated macrophages can promote carcinogenesis, angiogenesis and
immune escape.
Macrophages express major histocompatibility complex (MHC)
class I and II. Thereby, they can present tumor antigens through
MHC  II to CD4+ T cells and can cross-present MHC-I to
CD8+ T cells [72]. Following activation by toll-like receptors
such as lipopolysaccharide (LPS) or interferon-gamma (IFN-),
macrophages upregulate costimulatory molecules such as MHC-
class I, CD80, CD83 and CD86, enabling T cells to fully mature
and mount an antigen-speciﬁc immune response [73]. However,
in a tumor microenvironment, macrophages do not appear able to
present antigens. This may  be reversible. Thus, IL-12 can convert
M2 into M1  macrophages. This can enable antigen presentation to
CD8+ T cells and improved anti-tumor immunity [74].
TAMs can contribute to tumorigenesis by inducing the expres-
sion of immune checkpoints on tumor cells. For example, TAMs can
induce the expression of programmed death-ligand 1 (PD-L1) [73].
This can engage the PD-1 receptors on T cells and inhibit their abil-
ity to respond to tumor antigens. Therapies that block PD-1 and
PD-L1 may be effective for the treatment of many types of cancer.
[75,76]. In general, increased TAMs correlates with poor prognosis
of patients [77,78]. Hence, therapies that target TAMs or alter their
function may  be useful for the treatment of cancer.
2.4. IDO
DCs are antigen-presenting cells that link the innate and adap-
tive immunity and have been implicated in the immune regulation
of cancer [79,80]. DCs are key players in inducing anti-tumor
immune responses. DCs exposed to antigen in the absence of the
correct costimulation can induce tolerance [81]. The tolerogenic
function of DCs has been associated with low levels of speciﬁc
molecules including the B7 family members and PD-L1, B7-H2,
B7-H3, B7-H4 and BTLA [82–89].
The immune tolerance mediated by DCs appears to be medi-
ated by enzymes that negatively regulate the function of effector
lymphocytes in an antigen-independent fashion. These include
inducible nitric oxide synthase, which generates nitric oxide,
arginase-1, which depletes the milieu of arginine, and IDO, which
degrades the essential amino acid tryptophan (TRP) and catalyzes
the generation of kynurenine (KYN) [90–95].
The immune system can serve a protective role against tumor
development [96–100]. DCs harboring active IDO have been
detected in the tumor microenvironment or draining lymph nodes
[101–103]. These cells can suppress T cell functions via IDO acti-
vation by two  mechanisms. In the case of KYN, upon interaction
with the aryl hydrocarbon receptor, this molecule has been shown
to inhibit proliferation of T cells and NK cells, promote regulatory
T cell (Treg) differentiation, and inhibition of DC immunogenicity
[90,91,104]. In addition, rapid TRP depletion from the microen-
vironment sends stress signals to T cells, inducing anergy in CD8
cytotoxic T cells and promoting CD4 differentiation toward Tregs
[90,91,105].
Tumor cells can synthetize IDO. But, it is not clear if the major
contributors to KYN generation and TRP depletion in the tumor
microenvironment are tumor cells or inﬁltrating leukocytes, in
particular DCs or TAMs [90,91,106]. Regardless of the source,
IDO activation can induce immunosuppression. High levels of IDO
are correlated with poor prognosis [107–112]. IDO inhibition can
suppress tumor growth in mouse models [113–117]. Hence, IDO
inhibitors may  be useful to target the tumor microenvironment for
the treatment of cancer.
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.5. VEGF
VEGFs are critical regulators of tumor angiogenesis. They com-
rise a family (VEGF-A, -B, -C, -D, -E and placenta growth factor
PGF]) of growth factors that show a conserved pattern of eight cys-
eine residues [118–120]. In particular, VEGF-A (the paradigmatic
olecule of this family and usually referred to as VEGF) has the
apability to act both as a mitogen, stimulating the proliferation of
ndothelial cells, and also a chemotactic factor with the capability
o attract monocytes [118–120].
Human VEGF-A has four different isoforms (VEGF 121, 165,
89 and 206), a consequence of alternative exon splicing [118].
he properties of native VEGF most closely correspond to that of
EGF-165, which is the predominant VEGF-A isoform [118]. VEGF
articipates in different physiological processes such as angiogen-
sis, wound healing, and embryogenesis [118–120]. VEGF has been
hown to participate in pathological processes such as diabetic
etinopathy and oncogenesis [118]. Tumors require angiogenic fac-
ors to induce the formation of neovessels [121–123]. VEGF alone
an initiate the angiogenic cascade [124]. VEGF is secreted by most
uman cancers [124], and VEGF expression can be correlated with
 poor prognosis in ovarian [100] and other types of cancer tumors
125–128].
VEGF interacts with common receptors (VEGFR-1, VEGFR-2,
EGFR-3 and neuropilin-1) [129]. They comprise a family of recep-
or tyrosine kinases (RTKs) showing several immunoglobulin-like
omains in the extracellular domain, a single transmembrane
egion and a consensus tyrosine sequence that is interrupted by
 kinase-insert domain [118–120]. VEGF-A also interacts with the
europilins family of co-receptors.
VEGFR-1 has a very high afﬁnity for VEGF-A [130]. VEGF-A
revents binding to VEGFR-2 [118]. VEGFR-1 is able to induce mito-
enic and pro-survival signal in some cells [131]. VEGFR-1 also
as been linked to the induction of angiogenic molecules such
s matrix metalloproteases (MMPs) and hepatocyte growth factor
HGF) [132,133]. VEGFR-1 may  also participate in hematopoiesis,
ecruitment of endothelial progenitors, and migration of mono-
ytes. Finally, VEGFR-1 can heterodimerize with VEGFR-2, leading
o a transactivation of this molecule [134].
VEGFR-2 mediates mitogenesis and angiogenesis [118–120].
pon ligand binding, VEGFR-2 dimerizes and autophosphorylates
n multiple tyrosine residues. Ligation of VEGFR-2 by VEGF results
n the phosphorylation of different proteins such as PI-3-kinase,
AS GTPase-activating protein, the SRC protein family, and the
roteins from the RAF-MEK-ERK pathway [119,120,135]. VEGFR-
 signaling can promote endothelial cell survival, proliferation and
ngiogenesis. Thus, VEGF and its receptors are considered to be
ey molecules in the neovascularization process and consequent
rowth of many tumors.
VEGF has been the target for antitumor therapies [136].
 humanized monoclonal antibody targeting VEGF (beva-
izumab/avastin) has been approved for treatment of different
olorectal cancer, renal cancer, lung cancer or glioblastoma [137].
ome studies highlight its efﬁcacy as part of combinatorial thera-
ies [138–140]. Aﬂibercept/VEGF-trap can act as a decoy receptor
or VEGF. This compound has antitumor efﬁcacy [137,141–144].
inally, RTK inhibitors such as sunitinib and sorafenib have activity
n gastric cancer, renal cancer, pancreatic tumors or hepatic cancer
137,145].
.6. FibrosisTissue ﬁbrosis is commonly observed in the tumor microen-
ironment associated with rapid proliferation of ﬁbroblasts
67]. Fibroblasts also can secrete various cytokines and
hemokines such as TGF-, IL-1, IL-6, IL-8, CXCR4, CXCL12, and Biology 35 (2015) S199–S223
monocyte-chemotactic protein 1 (MCP-1) [146] and platelet-
derived growth factor (PDGF), HGF, stromal-cell-derived factor 1
(SDF1), VEGF, and basic ﬁbroblast growth factor (bFGF) [147].
Cancer associated ﬁbroblasts (CAF) are often linked to more
aggressive tumor biology due to the secretion of MMPs  that
enhance the breakdown of the ECM and aid in cancer cells escaping
into the vasculature and metastasizing to distant sites [148]. MMPs
are also implicated in inducing epithelial to mesenchymal transi-
tion (EMT), a process that triggers the de-differentiation of cancer
cells of epithelial origin into mesenchymal cells with properties of
stemness. EMT  may be a biomarker of poor prognosis [149]. Fibro-
blasts can be associated with a worse clinical outcome in patients
with many types of cancer [150–152]. Thus, the targeted inhibition
of ﬁbroblasts may  be useful for treating cancer.
However, some studies suggest a more complex role for ﬁbro-
blasts in tumorigenesis. Targeting the ﬁbroblast activating protein
(FAP) did not result in tumor regression but was associated with
bone marrow toxicity [153]. The targeted deletion of smooth
muscle actin positive myoﬁbroblasts speciﬁcally associated with
pre-malignant stages of pancreatic carcinomas (pancreatic intraep-
ithelial neoplasia) [154]. This led to a more poorly differentiated and
aggressive tumor phenotype. Hence, ﬁbroblasts and myoﬁbroblasts
appear to play a critical role in the formation of the extra-cellular
matrix and inducing ﬁbrosis within growing tumors.
2.7. IL-6
IL-6 is an inﬂammatory cytokine associated with innate immune
responses and defense against infection, but was  more recently
found to play a role in the tumor microenvironment. Macrophages,
monocytes and T cells can produce IL-1 and TNF [155]. The
dysregulation of IL-6 is associated with inﬂammatory diseases,
such as rheumatoid arthritis, insulin resistance, sepsis and cancer
[155,156].
Signaling of IL-6 occurs through the collaboration of a
membrane-bound receptor (IL-6R/gp80) and signal transducer
glycoprotein (gp130), a receptor for cytokines such as IL-11 and IL-
27 [155–158]. The expression of surface IL-6R is limited mostly
to immune cells and hepatocytes. However, gp130 is ubiquitously
expressed by many cell types, including endothelial and tumor cells
[157,159–161]. The soluble form of the IL-6R (sIL-6R) is able to
interact with IL-6 in solution and then contact the cell membrane
to induce signaling through gp130. Thus, cells lacking membrane-
bound IL-6R can still be inﬂuenced by IL-6 generated in the
microenvironment [157,159–162]. IL-6 activates JAK and the signal
transducers and activators of transcription (JAK/STAT) activating
STAT3 [155,163,164]. STAT3 leads to cancer cell survival, prolifera-
tion, and metastasis; it also promotes angiogenesis and expression
of immune suppressive factors in the tumor microenvironment
[165]. IL-6 can promote growth of breast cancer [166], glioma [167],
lymphoma [168], multiple myeloma [169], ovarian cancer [170],
and prostate cancer [171]. High levels of soluble IL-6 or high lev-
els of IL-6 staining in tumor samples correlate with poor outcome
[172–181]. Finally, IL-6 can induce the production of VEGF in cancer
cells or tumor-associated cells [182–184]. Thus, IL-6 can promote
tumorigenesis through many mechanisms.
IL-6 has been therapeutically targeted. Anti-IL6 antibody (siltux-
imab/CNTO 328) increases the cytotoxic effect of chemotherapeutic
drugs such as paclitaxel or melphalan [185–187] and decreased
tumor growth, macrophage inﬁltration and angiogenesis [185]. Sil-
tuximab alone or in combination with cytotoxic drugs has been
studied in human patients [188–190]. Some effect was  observed
when used in combinatorial therapies [191,192]. Similarly, a
humanized anti-IL-6R antibody, tocilizumab, has been shown to
inhibit IL-6 signaling in cancer cells in preclinical studies [193–195].
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his antibody has been used for the treatment of inﬂammation
196] and cachexia [197].
.8. Endoglin
Endoglin (CD105) is a homodynamic glycoprotein growth fac-
or co-receptor for TGF- in endothelial tissue that plays a critical
ole in angiogenesis and vascular remodeling [198,199]. Endoglin
odulates SMAD phosphorylation and may  control cell adhesion
nd migration by regulating the composition of focal adhesion
omplexes and can regulate angiogenesis. Aberrations of its co-
eceptor function are critical to many cell processes implicated
n cancer [200]. Inﬂammation and tumor-associated angiogenesis
ay  result from dysregulation of endoglin co-receptor functions
201]. Endoglin expression is observed in neo-angiogenesis, tumor
rogression and metastasis [202]. Inhibiting the endoglin path-
ay may  be useful for the treatment of cancer [203,204]. The
RC105 antibody has high avidity for endoglin-binding and may
ave activity as a single agent as well as combined chemotherapy
ith bevacizumab [205] and may  overcome therapeutic resistance
o bevacizumab [206].
.9. JAK
The JAK family includes the receptor-associated tyrosine kinases
AK1, JAK2, JAK3 and Tyk2 that are important regulators of many
ormal signaling processes that have been implicated causally in
umorigenesis [207,208]. The JAK pathway is generally critical to
ormal cellular signaling [209,210]. Among classical examples is
he JAK-mediated STAT3 tyrosine phosphorylation in response to
L-6 family cytokines (including IL-11) signaling through GP130
211].
Mutations in JAK2 and more commonly in SOCS1 have been
mplicated in tumorigenesis [212]. The JAK/STAT3 pathway is
onstitutively active in the tumor cells [213,214] and in tumor
ssociated stromal cells [163,164,184,215,216]. IL-6 – mediated
AK/STAT paracrine signaling is commonly observed in cancer
217–219].
JAK signaling is important to tumor–host interactions in the
icroenvironment. In head and neck cancer, IL-6 mediates EMT
nd increases metastatic potential of transformed cells [220]. In
aldenstrom macroglobulinemia, dysregulated CCL5 expression
odulates IL-6 secretion in stromal cells, resulting in increased
gM secretion by malignant cells via the JAK/STAT pathway [221].
ancreatic cancer-associated stellate cells secrete IL-6 and other
oluble factors that promote the accumulation of myeloid-derived
uppressor cells via the JAK/STAT3-dependent mechanism [222]. In
ung carcinogenesis, AZD1480 inhibits STAT3 activation in tumor-
ssociated myeloid cells, reduces cell number, inhibits tumor
etastasis, and myeloid cell-mediated angiogenesis. AZD1480
locks angiogenesis, lung inﬁltration of myeloid cells and forma-
ion of pulmonary metastases in mouse syngeneic experimental
nd spontaneous metastatic models as well as in human xenografts.
TAT3 activation in cancer cells is sufﬁcient to overcome the
icroenvironment-mediated and AZD1480-inhibited lung cancer
rogression [223].
The therapeutic effects of the TLR4 and TLR9 agonist complexes
gainst melanoma metastasis are dependent on the simultaneous
se of inhibitors of the JAK/STAT pathway (such as the AG490 antag-
nist). Such combined therapy activates the autophagy-associated
eath of melanoma cells via IFN-/STAT1 activation and attenu-
ted tumor metastasis [224]. In Barrett’s carcinogenesis, the IL-6
locking antibody and AG490 and JAK inhibitor I blocks STAT3
hosphorylation decreasing resistance to apoptosis [225]. The
AK/STAT3-dependent accumulation of Treg cells in tumors is
ependent on an increase in S1PR1 protein in CD4+ T cells, while Biology 35 (2015) S199–S223 S207
the JAK/STAT3 pathway inhibition in T cells diminishes accumula-
tion of Treg cells in tumors and tumor growth. The Treg migration
toward tumors is nearly completely blocked by AZD1480 [226].
The GP130-IL6ST/JAK1 signaling generates actomyosin contractil-
ity through Rho-kinase dependent signaling in both the tumor cells
and the stromal cells. Hence, the inhibition of the JAK pathway
could be useful to modulate tumorigenesis through many mech-
anisms, including targeting the tumor microenvironment.
3. Approaches
3.1. Berberine
Berberine (Fig. 2) is quaternary ammonium salt from the
protoberberine group of isoquinoline alkaloids with general anti-
neoplastic properties [227,228]. Berberine has a low bioavailability
with less than 5% of the ingested dose ﬁnding its way  into the sys-
temic circulation [229,230]; in rats the value is considerably lower
(0.68%) [231]. In humans, doses of 1000–1500 mg  per day have been
shown to be effective in regards to berberine’s impact on glucidic
and lipidic proﬁles in patients with hypercholesteremia and type
2 diabetes. The metabolized product of berberine also acts as an
original compound but with less potency [232,233]. The common
form of the urinary excreted product of berberine is believed to be
jatrorrhizine [234,235].
As a traditional medicine or dietary supplement, berberine
has shown activity against fungal, Candida albicans, parasitic,
and bacterial/viral infections [236]. Its clinical utility has been
assessed for many diseases and conditions including hyperlipi-
demia, diabetes, obesity and fatty liver disease. Currently there
are 17 completed and ongoing registered clinical studies regarding
berberine (www.clinicaltrials.org).
Berberine’s interactions with a variety of metabolic pathways
have been widely investigated. Adenosine mono-phosphate kinase
(AMPK) is a nutrient sensor protein; berberine activates AMPK in
a dose and time-dependent manner [237,238]. The data suggest
that berberine-induced AMPK inhibits complex I of the mitochon-
drial electron transport chain [239]. This effect is also observed
with the anti-diabetic drugs metformin and rosiglitazone. In lipid
metabolism, the lipid-lowering effect of berberine is believed to
be related to stabilization of the hepatic LDL-C receptor (LDLR)
by an ERK-dependent pathway and also by increased transcrip-
tional activity of LDLR promoter by a c-Jun N terminal kinase (JNK)
[240,241]. In 3T3L1 cells, berberine has been shown to reduce key
adipogenic enzymes in vitro such as fatty acid synthase, acetyl-
coenzyme A (acetyl-CoA) carboxylase, acyl-CoA synthase, and
lipoprotein lipase [242]. Furthermore, berberine has been shown
to inhibit cholesterol and triglyceride synthesis in hepatic cells via
activation of AMP  kinase [243].
Berberine’s anti-neoplastic effects have been noted [244,245].
Berberine appears to suppress inﬂammation in response to
pro-inﬂammatory stimuli [246]. Berberine at 10–20 mcg/mL con-
centrations, in vitro, has been shown to slightly increase T cell
proliferation in response to antigens, while concentrations above
that level result in dose-dependent immunosuppression [247].
The selective inhibition of JAK3 by berberine may also mediate
immunosuppression [248]. Berberine exerts its anti-tumor effects
via various mechanisms that include inhibition of cell proliferation,
induction of apoptosis, and suppression of angiogenesis and tumor
metastasis. Berberine’s immunomodulatory effects, via JAK3 inhi-
bition, might also impact cancer growth [248]. Berberine has been
found to enhance the cytotoxicity of doxorubicin, which suggests
that this agent may  have potential as an adjunct to some traditional
chemotherapeutic agents [249]. The cytotoxic effect of berberine
has been demonstrated for a wide variety of tumors including lung,
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reast, prostate, colorectal neuroblastoma, lymphoma, osteosar-
oma and leukemia [228].
Berberine has a caspase-independent apoptotic effect on the
MCE colon cancer cell line but not a normal colonocyte cell line,
AMC [250]. Berberine also induces cytotoxicity via G1-phase cell
ycle arrest and caspase-3-dependent apoptosis in glioblastoma,
pidermoid and prostate carcinoma cells [251–253]. The apoptotic
ffect of berberine is associated with upregulation of the pro-
poptotic genes Fas, FasL, p53, and Bax [254–256]. Berberine has an
nti-angiogenic effect related to decreased expression of MMP-1,
MP-2 and MMP-9 [257–259].
As a quaternary ammonium, berberine’s solubility is low.
erberine use is hampered by its low bioavailability which is
elated to it rapid biotransformation during the lengthy period
hat it remains in the intestine. Various nano-particulate delivery
ystems have been used to increase the absorption of berber-
ne, including the rotary-evaporated ﬁlm-ultrasonication method
260], nanoemulsiﬁcation with isopropyl myristate/glycerin [261],
nd lipisomal incorporation [262]. Berberine manufactured with
he nanoparticulate delivery systems demonstrated improved
ioavailability and optimization of its anti-inﬂammatory, anti-
ngiogenic [263], and anticancer effects [264]. Berberine has
otential as an anti-cancer agent [250]. The molecular basis of its
eoplastic effects, however, needs to be further investigated.
.2. Resveratrol
Resveratrol (3,4′,5-trihydroxy-trans-stilbene) is a polyphenolic
ompound that functionally belongs to phytoalexins with anti-ROS
ctivity. Resveratrol is produced through stilbene synthase [265]
n response to pathogen infections [266] or stress conditions [267]
sing malonyl-coenzyme A (CoA) and p-coumaroyl CoA as precur-
ors. This compound may  have potential for cancer prevention and
reatment [268].
Resveratrol is naturally occurring in more than 70 plant species
ncluding peanuts, blueberries, raspberries, mulberries, pine, and
rapes [269]. Relatively high levels of resveratrol present in fresh
rape skin, which explain its high concentrations in red wine and
rape juice [270]. Different conjugated forms of resveratrol were
etected in plants. Trans-resveratrol exists in glycosylated forms
nd has cis and trans isomers. Other conjugations, including 1–2
ethyl groups, sulfate group, and fatty acids, were also observed
270]. Glycosylation increases stability, solubility and absorption in
uman gastrointestinal tract. Additionally, it protects resveratrol
rom oxidative degradation [271].
Resveratrol metabolism in human body includes its con-
ersion to water-soluble trans-resveratrol-3-O-glucuronide and
rans-resveratrol-3-O-sulfate by liver phase-2 drug-metabolizing
nzymes [272]. These metabolic products have a plasma half-life of
bout 9.2 h, which is signiﬁcantly higher than the half-life of resver-
trol (8–14 min) [272]. Concentrations between 32 nM and 100 M
ere used for different in vitro studies, while concentrations of
00 ng to 1500 mg/kg (body weight) were used in animal studies
273]. Resveratrol and its metabolism products were detected in
iver, stomach, kidney, bile and urine after a single oral administra-
ion of 14C-trans-resveratrol in Balb/c mice [274], whereas 24.6% of
esveratrol and its metabolites were detected in human urine after
ral administration [275].
The biological activity is associated only with the trans form,
hich is a free radical scavenger [276]. Normal cellular respira-
ion, environmental stress, and UV radiation are the main inducers
f ROS production. The imbalance in the ratios between oxi-
ized and reduced redox couples like glutathione (GSH/GSSG) or
ADPH/NADP+ cause ROS accumulation [277]. High levels of ROS
eact with cellular components including DNA, proteins, and lipids
eading to cellular and tissue damage [278]. Resveratrol and other Biology 35 (2015) S199–S223
dietary stilbenes reduce oxidative stress by acting either as a
direct scavenger of ROS [279] or as an inhibitor of NADPH oxidase
expression and xanthine oxidase activity [280]. Resveratrol has low
toxicity [281]. Various studies report anti-cancer effects [282–284],
including the suppression of metastasis [285] and induction of pro-
liferative arrest [286].
Normal cells have antioxidant enzymes and molecules that keep
ROS under normal physiological levels [287]. In cancer cells, onco-
genic signals stimulate active cellular metabolism, which increase
ROS production and cause permanent oxidative stress [288].
Additionally, tumor associated mitochondrial malfunction cause
massive increases in ROS production [289]. Resveratrol inhibits ROS
and reduces oxidative stress [290]. It decreases intracellular ROS
production and oxidative stress by mechanisms involving degra-
dation of Keap 1 protein, which is a repressor of Nrf2 [291]. In a rat
model of hepatocarcinogenesis, resveratrol was  found to upregu-
late hepatic Nrf2 [292]. In another study, the total oxidant levels in
plasma, liver and brain were decreased and total antioxidant lev-
els in these organs were increased in rats treated with resveratrol
[293]. Additionally, resveratrol reduced oxidative stress and main-
tained mitochondrial function through its ability to activate sirtuin
1 (SIRT1), which has many roles in reducing oxidative stress and
promoting mitochondrial functions [294]. Moreover, it decreased
serum and hepatic oxidative stress in high-fat diets [295] and dia-
betic rats [296]. Resveratrol is a candidate for the treatment and
prevention of different cancers by the inhibition of ROS.
3.3. Onionin A
Onionin A is a natural product in Allium vegetables that
has recently been identiﬁed as a potential agent to regulate
macrophage activity that could have anti-neoplastic activity. The
consumption of Allium vegetables is associated with a decreased
risk of several cancers. A European epidemiological study reported
a 55–80% reduction of odds ratios of almost all major cancers,
including oral, esophageal, laryngeal, colorectal, prostate, breast
and ovarian cancers, in populations who frequently consumed
considerable quantities of onions or garlic in their meals [297]. Veg-
etables including onions, garlic, leaks, chives and scallions belong
to the Allium family. Previously identiﬁed bioactive compounds in
onions (Allium cepa) are ﬂavonoids and phenols [298]. Flavonoids
are the largest family of polyphenolic compounds and as such
the names “polyphenols” and “ﬂavonoids” may, at times, be used
interchangeably. These compounds are believed to limit and deter
the development of cancers from damaged cells via their anti-
inﬂammatory effects [299–302].
The cytotoxic effects of onion-derived polyphenol extracts have
recently been investigated. The polyphenol extract from A. cepa can
induce caspase dependent apoptosis of human gastric cancer cells
via a mitochondrial pathway by upregulating p53 and Bax proteins
as well as by modulating Bcl-2 proteins. Furthermore, onion-
derived polyphenol extract induced caspase-dependent apoptosis
of several human leukemia cell lines in vitro has been attributed, at
least in part, to inhibition of the PI3K/AKT signaling pathway [303].
The antioxidant and antimutagenic properties of onion extract
against mutagens are related to their polyphenols and ﬂavonoids
[304]. The lipid soluble organosulfur compounds present in onion
extracts inhibit proliferation of cultured human colon, skin and lung
tumor cells [305]. One possible mechanism for the inhibition of car-
cinogen activation by onion extract derivatives may  be inhibition of
cytochrome P450 2E1, which is activated by a number of xenobiotic
substances [306].Onions are also rich in organosulfur compounds. These phyto-
chemicals, including diallyl disulﬁde, S-allylcysteine and ajoene,
protect against chemically induced cancer in animal models by
altering carcinogen metabolism [307–310]. Recently, onionin A was
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uriﬁed [311] and identiﬁed as a 3,4-dimethyl-5-(1E-propenyl)-
etrahydrothiophen-2-sulfoxide-S-oxide. Onionin A may  inhibit
AMs [68,312]. The toxic effect of onionin A on IL-10-induced acti-
ation of M2  macrophage by assessing the expression of the unique
2  marker CD163. Onionin A signiﬁcantly suppressed the expres-
ion of CD163 at concentrations of 10 and 30 M.  These results
uggest that onionin A may  suppress tumor cell proliferation. This
gent may  be useful as an anti-cancer agent.
.4. EGCG
EGCG inhibits IDO expression in human cancer cells. Consump-
ion of green tea, which is produced from the leaves of Camellia
inensis plant, has been associated with lower incidence of human
ancer [313]. Green tea contains many polyphenols, in particu-
ar EGCG, which have been shown to suppress tumor formation
nd progression in animal models [314]. The chemopreventive and
herapeutic effects of EGCG are attributed to the broad-spectrum
nti-cancer abilities of this polyphenol, including inhibition of pro-
iferation, inﬂammation, apoptosis, and angiogenesis [314,315].
EGCG has also been found to inhibit the expression of IDO,
hich is a key enzyme in suppressing T cells and inducing
mmune tolerance to tumor cells through depletion of tryptophan.
any cytokine-dependent and independent signaling pathways
re involved in IDO expression. Interferon-stimulated IDO acti-
ation is, however, mediated by the JAK/STAT signaling pathway
316]. There is a number of evidence suggesting that EGCG inter-
eres with JAK/STAT-regulated IDO activation, resulting in the
uppression of IDO and IDO-related downstream gene expression
n human cancer cells.
EGCG has been shown to suppress IDO expression through
nhibiting IFN- induced in human oral cancer cell lines [317].
he translocation of STAT1 into the nucleus, which consequently
nhibits the transcriptional activation of IDO, was blocked by EGCG.
hen et al. [317] also showed that EGCG signiﬁcantly suppressed
he phosphorylation of protein kinase C (PKC-)  and JAKs, resulting
n inhibition of IFN--stimulated STAT1 phosphorylation. Simi-
arly, another group demonstrated that EGCG blocks IDO expression
n human colorectal cancer at the transcriptional level through
nhibition of STAT1 phosphorylation, which consequently sup-
ressed the activity of STAT1-activated sequence elements of the
DO promoter, IFN-stimulated response element (ISRE) and IFN--
ctivation sequence (GAS) [318].
EGCG was found to exhibit anti-IDO activities in murine bone
arrow-derived dendritic cells (BMDCs) [319]. EGCG blocked
he binding of phosphorylated STAT1 to INF regulatory factor-1
IRF-1) promoter, in response to IFN- stimulation. The expres-
ion of prostaglandin E2 (PGE2) and cyclooxygenase (COX-2) was
lso signiﬁcantly inhibited in EGCG-treated murine BMDCs. Over
xpression of PGE2, a bioactive lipid, and COX-2, the key enzyme
n prostaglandin biosynthesis, is often associated with immune
urveillance and cancer [320]. The inhibitory effect of EGCG on COX-
 expression has also been seen in other cancer cell lines such as
uman prostate carcinoma and colon carcinoma [321,322]. In an
n vivo study, Ogawa et al. [323] demonstrated the effect of EGCG
n azoxymethane (AOM)-induced preneoplastic lesions in F344 rat
hrough suppression of IDO expression. EGCG-treated rats exhib-
ted signiﬁcantly reduced levels of aberrant crypt foci, which had
verexpression of IDO. The mRNA expression of COX-2 in AOM-
reated rat was  also inhibited by EGCG treatment [323].
EGCG inhbits the JAK/STAT signaling pathway. Pre-treatment
ith EGCG lead to suppression of STAT1 phosphorylation and IRF-1
xpression on different cancer cell lines such as mammary carci-
oma, cervical carcinoma, and hepatocarcinoma [324,325]. STAT3
s associated with constitutive IDO expression in human cancer
ells [326]. EGCG inhibits the phosphorylation and expression of Biology 35 (2015) S199–S223 S209
both JAK3 and STAT3 proteins in pancreatic cancer cells [327]. EGCG
decreases the levels of phosphorylated-STAT3 proteins stimulated
by insulin-like growth factors (IGFs) in hepatocellular carcinoma
cells, possibly through inhibiting the bioavailability of IGFs [328].
EGCG inhibits STAT3 in head and neck cancer [329] and breast can-
cer [330]. The inhibition of the JAK/STAT pathway through EGCG
may  be useful to regulate IDO.
EGCG has anti-cancer properties. The ability of EGCG to act
as a multi-targeting agent in regulating JAK/STAT signaling and
JAK/STAT-mediated IDO is remarkable. The combinative efﬁcacy
of EGCG with a number of chemotherapeutic drugs such as tamox-
ifen and paclitaxel has shown synergistic effect [331], EGCG is a
candidate as a cancer therapy by targeting IDO.
3.5. Genistein
Genistein (4′,5,7-trihydroxyisoﬂavone), a polyphenolic
isoﬂavone, is found in soy products and appears to modulate
cholesterol metabolism. It has low bioavailability due to poor water
solubility, extensive intestinal ﬁrst-pass phase II metabolism, and
subsequent excretion of their conjugated metabolites [332]. Epi-
demiological studies suggest that intake of soy rich diet may  lower
the incidence of breast and prostate cancer in Asian countries
[333,334]. Genistein may  mediate its anti-cancer effects through
nuclear factor (NF)-B modulation, reduction of AKT protein level,
downregulation of androgen-mediated carcinogenesis, and/or
more general antioxidation effects [334,335]. Genistein has poten-
tial anti-cancer activity against prostate [336,337], ovarian [338],
breast [339], lung [340], and pancreatic cancer [341].
Elevated HMGR activity, mevalonate, and protein prenylation
is associated with tumorigenesis [342]. Genistein has been shown
to suppress HMGR and inhibit tumor growth [343,344]. Genistein
also can increase LDL receptor and decrease HMGR expression in
colon cancer cells [345]. Genistein has many other effects on lipid
metabolism that could contribute to its anti-neoplastic properties
[346]. However, it is important to note that genistein may  have
pro-proliferative effects in some contexts [347–350].
3.6. Curcumin
Curcumin (diferuloylmethane), the active ingredient of the
turmeric spice from plant Curcuma longa, belongs to the group of
polyphenolic herbal compounds and has multiple beneﬁcial effects
including anti-tumorigenic action that appears to be related to
VEGF inhibition. Powder of turmeric is widely used in Ayurveda,
Unani, and Siddha medicine as a home remedy for various dis-
eases [351]. In addition to curcumin, turmeric contains minor
fractions such as demethoxycurcumin, bisdemethoxycurcumin,
and the cyclocurcumin [352]. Curcumin has been implicated as
suppressor of tumor initiation and promotion, angiogenesis, and
metastasis [353,354].
Curcumin downregulates the expression of VEGF in prostate
cancer cells in a dose-and time-dependent manner [355]. Osteo-
pontin/integrin avb3 signaling through MMP9  activation increases
VEGF and angiostatin expression in prostate cancer cells and
conversely curcumin reduces VEGF expression [355], suppresses
MMP9  activity in prostate cancer cells. The curcumin-derived ana-
logue CDF inhibits VEGF as well as IL-6 and cancer stem cell
signature genes Nanog, Oct4, and EZH2 in vitro and in vivo [356].
Similarly, CDF reduced VEGF and IL-6 expression in prostate cancer
cells [357]. Curcumin inhibited migration and invasion of human
lung cancer cells through inhibition of MMP-2 and MMP-9 and
suppression of VEGF expression [358]. Long-term exposure to cur-
cumin was investigated in the liver of lymphoma-bearing mice.
Curcumin treatment induced activation stress activated genes HIF-
1a, MYC, and LDH activity to normal levels. Furthermore, it led to
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nhibition of angiogenesis as evidenced by reduced MMP-2, MMP-9,
KC-a and VEGF levels [359].
Similar to IL-6, IL-1 signaling is crucial to inﬂammatory and
alignancy processes. IL-1 induced IkB alpha phosphorylation and
nhibition of downstream NF-B, which leads to expression of sev-
ral genes that are associated with cell proliferation, invasion and
ngiogenesis [360]. Curcumin treatment blocked IL-1 and VEGF
xpression in chondrosarcoma cells. Further, curcumin inhibited
L-1 beta-induced angiogenesis and NF-B-related gene expres-
ion [361]. Curcumin is one of the main constituents of turmeric
pice, which has been used for centuries. A phase 1 human trial
ith 25 subjects using up to 8000 mg  of curcumin per day for 3
onths found no toxicity, and overall it has been considered to be
afe in six human trials [362]. Curcumin has extremely low sys-
emic bioavailability, owing to its low aqueous solubility and poor
tability.
.7. Naringenin
Naringenin has good prospects as an ideal therapeutic agent vis-
-vis an inﬂuence on metastasis and speciﬁc effect on ﬁbrosis [363].
aringenin signiﬁcantly reduces lung metastases in mice (C57BL/6
nd BALB/c) with pulmonary ﬁbrosis and increases their sur-
ival by improving the ﬁbrotic-immunosuppressive environment
nd reducing regulatory T cells [364]. In HSC-T6 cells, naringenin
xerts antiﬁbrogenic effects by directly or indirectly downreg-
lating Smad3 protein expression and phosphorylation through
GF-beta signaling [365] and the downregulation of vimentin, N-
adherin, MMP2  and MMP9  [366]. Naringenin inhibits the viral
ssembly and long-term production of infectious hepatitis C par-
icles [367]. It possesses agonistic [368] and antagonistic activities
oward estrogen [369]. This also might its protective value against
he food contaminant bisphenol A [370]. Hence, naringenin exerts
nhibitory effects on cancer cell growth, migration and invasion,
nd also possess chemopreventive property.
Naringenin has low bioavailability (2.8% of intake) due
o high excretion and low Cmax in plasma. The principal
etabolites, naringenin-7-O-glucuronide and naringenin-4′-O-
lucuronide peaks at 6 h after intake [371]. The distribution of
etabolites also varies due to binding of metabolites to human
erum albumin [372]. The binding modulates the half-life in
lasma and tissue distribution. A NRG glucuronide have same
fﬁnity for human serum albumin as naringenin. Efforts are in
ay to increase the bioavailability through various techniques
ike combining NRG with -cyclodextrin through solid disper-
ion and self nano emulsifying drug (SNEDDS) technique [373].
he mixture and nanoparticles enhanced a signiﬁcant increase
n NRG absorption compared to NRG alone. Area under the drug
oncentration time curve (AUC) 0–24 h was signiﬁcantly higher
or SNEDDS as compared with pure drugs. Even NRG-loaded
anoparticles showed enhanced anti-lipid peroxidative antipro-
iferative effect and antioxidant potentials owing to increased
hemo-preventive efﬁcacy compared to free naringenin in 7,12-
imethylbenz(a)anthracene (DMBA)-induced oral carcinogenesis
374]. Naringenin ﬂavonoids present in GJF demonstrate multiple
nteractions with drugs leading to loss of the therapeutic effects
r increased side effects through a competitive or mechanism
ased inhibition of gut wall CYP3A4 isoenzyme, P-glycoprotein
ulti-drug resistance protein, and organic anion transporting
olypeptide inhibition. Its safety has also been evaluated through
n vitro and in vivo studies [375,376]..8. Desoxyrhapontigenin
Desoxyrhapontigenin (3,5-dihydroxy-4′-O-methylresveratrol)
s an antioxidant [377]. Desoxyrhapontigenin may  be useful in the Biology 35 (2015) S199–S223
modulation of the tumor microenvironment. It inhibits cytochrome
P450 enzymes [378,379], inﬂammation, ROS, and associated path-
ways [380–385].
Desoxyrhapontigenin affects ROS and inﬂammation. This occurs
through increased expression of antioxidant enzymes [383] and the
inhibition of NF-B and AP-1, reduced production of COX-2, TNF-,
and IL-6, and reduced inﬂammation in a carrageenan-induced ani-
mal  inﬂammation model [385]. Desoxyrhapontigenin is produced
by plants [386] and its cyototoxic and anti-proliferative effects
are dose-dependent [387–390]. Thus, desoxyrhapontigenin may  be
useful as a therapeutic agent for cance through its effects on ROS
and inﬂammation.
3.9. Piperine
Piperine (1-piperoyl piperidine) is the principal alkaloid in black
(Piper nigrum) and long peppers (Piper longum) and has potentially
multiple anti-cancer activities. It is widely used both as a spice in
food as well as in traditional medicine [391].
Piperine has low toxicity [392]. Additionally, the in vitro absorp-
tion rate of piperine is relatively high compared with other natural
products like curcumin without any metabolic modiﬁcation of
piperine during the absorption process [393]. Piperine is widely
used as a bioavailability enhancer for a diverse group of thera-
peutic agents including the antimicrobial agent rifampicin [394],
nevirapine which is a potent inhibitor of human immunodeﬁciency
virus (HIV)-1 reverse transcriptase [395] and curcumin which has
anticancer properties [396]. Piperine has various biological effects
including antioxidant activity [397] as well as an anti-inﬂammatory
effect by inhibiting PMA-induced COX-2 [398].
Piperine has signiﬁcant anti-cancer effects [399]. Different
mechanisms have been suggested, including apoptosis and sup-
pression of metastasis [400], inhibition of angiogenesis [401], and
blocked invasion by downregulation of MMPs  [402,403]. Piper-
ine exerts chemopreventive activity against some carcinogens
including benzo(a)pyrene-induced lung carcinogenesis [404] and
DMBA-induced skin carcinogenesis [405]. Piperine, with its low
toxicity and potent anti-angiogenic activity, may  be considered as
a possible therapeutic agent in cancer prevention and treatment.
3.10. Zerumbone
Zerumbone, a sesquiterpene, exerts its anticancer effect through
modulation of the JAK/STAT pathway. In renal cell carcinoma
cell lines and xenograft mouse model, zerumbone dose- and
time-dependently, inhibits the activity of STAT-3 through sup-
pressing its upstream kinases c-SRC, JAK-1 and JAK-2. Pervanadate,
a protein tyrosine phosphatase (PTP) inhibitor treatment reversed
the zerumbone-induced downregulation of STAT3, suggesting the
involvement of a PTP. SHP-1 tyrosine phosphatase interacts with
STAT3 and is induced by zerumbone. Upon knockdown of SHP-1
by siRNA, the ability of zerumbone to inhibit STAT3 activation-
mediated apoptosis was  suppressed, suggesting the involvement
of SHP-1 in its action. Zerumbone not only suppresses STAT3 but
also reduces the expression of downstream STAT3-regulated gene
products that are involved in proliferation, survival, and angiogen-
esis [406]. Hence, zerumbone blocks STAT3 activation, leading to
suppression of growth and sensitization of cancer cells.
Zerumbone is an inhibitor of constitutive JAK/STAT as well as
IL-6 stimulated pathways, thereby blocking the activity of IL-6 in
pancreatic carcinoma [407]. A synergistic effect of zerumbone with
paclitaxel in prostate cancer cells is mediated through active JAK-
2/STAT-3 pathway [407,408]. Zerumbone with cisplatin showed a
synergistic anticancer effect on cervical intraepithelial neoplasia
in female BALB/c mice through serum IL-6 [409]. In some cases,
inhibition of JAK-2/STAT-3-mediated signaling pathways induced
ancer
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ytotoxicity through PARP cleavage in a human prostate cancer cell
ine (DU 145) [407]. However, other apoptotic mechanisms have
lso been reported through induction of G2/M arrest and decreased
yclin B1/CDK1 protein level in HL-60 cells [410]. G2/M arrest and
as- and mitochondria mediated-apoptosis have been observed
n T-acute lymphoblastic leukemia cells [411] and leukemia cells
412], and Bax- and Bak-mediated apoptosis has been observed
n human breast cancer cells and othotopic xenografts [413]. It
ay  modulate the Bax/Bcl-2 ratio in liver cancer cells independent
f functional p53 [414], TRAIL-induced death receptor in human
olon cancer [415], and Gli-1/Bcl-2 pathway mediated apoptosis in
uman renal carcinoma [416].
Zerumbone inhibited CXC chemokine receptor-4 expression
ith subsequent inhibition of CXCL-12 induced invasion of breast
nd pancreatic tumor cells [417] and human tongue squamous
ell carcinoma [417]. Zerumbone inhibited IL-6 and induces apo-
tosis in ovarian and cervical cancer cells [418]. It also decreased
he levels of nitrite and prostaglandin (E2) with unchanged COX-1
xpression in LPA and gamma  irradiated increased NO synthase
nd COX-2 as well as release of TNF- in RAW 264.7 mouse
acrophages [419–421]. Zerumbone suppressed TPA-induced
ctivation of EBV, LOX-1 mRNA expression [422], O2-anion gen-
ration through NADPH oxidase in DMSO differentiated human
romyelocytic leukemia (HL-60) cells and through xanthine oxi-
ase in AS52 Chinese hamster ovary cells [423]
The safety of zerumbone has been demonstrated in normal
uman cells [424]. Oral ingestion of zerumbone (20/40 mg/kg/day)
or 8 weeks reduced hyperglycemia induced p38 mediated inﬂam-
atory response (inﬁltration of macrophages and increased levels
f IL-1, -6 and TNF-) and also reduced expression of intercellular
dhesion molecule-1, MCP-1, TGF-1 and ﬁbronectin in nephro-
athic rats. The proven in vitro and in vivo pharmacological efﬁcacy
f zerumbone provides a base to elucidate anticancer bioactivity.
owever to increase the bioavailability, zerumbone-loaded nano-
tructured lipid carriers have also been prepared and characterized
or their antileukemic effect [410].
. Discussion: evaluating targets and approaches
We  have identiﬁed 10 potential approaches to inhibit 10 identi-
ed targets to treat and prevent cancer by targeting speciﬁc aspects
f the tumor microenvironment (Figs. 1 and 2, Tables 1 and 2). Our
ist is not exhaustive but more illustrative. Several themes have
merged.
First, the consideration of the tumor microenvironment as a
arget for cancer prevention and treatment provides a unique per-
pective on both tumorigenesis and therapy of cancer. The majority
f existing therapies have focused on the effect on the incipient
ancer cell. However, the inhibition of biological programs that are
ssociated with the tumor microenvironment may  be critical to the
revention and treatment of cancer.
Second, there are many existing natural products that have been
eported to have potential anti-neoplastic and/or tumor prevention
roperties. In many cases, these agents appear to have discrete and
eadily measurable effects on the host tumor microenvironment.
owever, it will be important to deﬁne the bioavailability as well
s the kinetics of elimination of these compounds when used alone
r in combination [425].
Third, the inﬂuence of agents that target the microenvironment
equires the development of unique assays. Most targeted therapies
an be evaluated through the examination of the expression and/or
ctivity of the molecule that is being targeted. The consideration
f the tumor microenvironment requires measurement of cellu-
ar, humoral, and cytokine mediated programs and this requires
n situ analysis. For many clinical studies, this is a problem since it
s not possible to obtain suitable clinical material for this evaluation. Biology 35 (2015) S199–S223 S211
Hence, the development of therapies that target the microenvi-
ronment requires novel approaches to make these measurements
either through more sensitive techniques that do not require direct
examination of tumor material or through measurements in more
easily obtained materials such as blood serum.
Fourth, the tumor microenvironment and incipient neoplastic
cells coevolve temporally during tumorigenesis. Hence, in target-
ing the microenvironment, one must recognize that it is critical
to consider when to introduce the therapeutic and to evaluate its
efﬁcacy at the right time. Thus, an agent that alters immune activa-
tion may  be critical in preventing tumorigenesis. Hence, it would
require examination of effects very early during tumor initiation
as opposed to in a preclinical model or patient with an advanced
cancer.
Fifth, the evaluation of agents that target the tumor microenvi-
ronment must be considered in the context of existing therapeutic
approaches for tumor prevention. Thus, for many cancers there are
accepted approaches for treating a primary or metastatic tumor,
or for reducing the chance of early cancer lesions for progressing
to more advanced cancers. Any considerations of the targets or
approaches we suggest have to consider the current standard of
care.
Sixth, the measurement of changes in the tumor microenviron-
ment may  be important endpoints for evaluating the preclinical
and clinical efﬁcacy of therapeutics. Examining how individually
or alone speciﬁc approaches are able to inﬂuence speciﬁc targets
could provide intermediate measurements suggestive of therapeu-
tic efﬁcacy.
Finally, we  realized that a broad multi-disciplinary approach
was important for identifying both approaches and targets. The
tumor microenvironment by its nature occurs in different biological
programs across multiple scales (molecule, cell, organ, host) over a
long time period. Investigators with skills across many disciplines
are required to consider this complexity.
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